You are here

Study: ‘Superbug’ Can Persist in Patients for More Than a Year After Initial Infection

Carbapenem-resistant organisms on rise in U.S. (Feb. 27)

Patients who tested positive for carbapenem-resistant Enterobacteriaceae (CRE) took an average of 387 days following hospital discharge to be clear of the organism, according to a new study published in the American Journal of Infection Control.

The study was conducted in the Shaare Zedek Medical Center, a 700-bed university-affiliated general hospital in Jerusalem, Israel. The research team analyzed follow-up cultures from 97 CRE-positive patients who had been discharged from the medical center between January 2009 and December 2010.

The average time until cultures became negative was 387 days. At 3 months, 78% of patients remained culture-positive; at 6 months, 65% remained positive; at 9 months, 51%; and at 12 months, 39% of patients remained positive, meaning they could potentially become re-infected or transmit the bug to others.

Risk factors for extended carriage included the number of hospitalization days, whether and how often the patient was rehospitalized, and whether the patient had an active infection as opposed to colonization without signs of active disease.

The authors state: “Patients with multiple hospitalizations or those who were diagnosed with clinical CRE disease should be assumed to have a more extended duration of CRE coverage and should therefore be admitted under conditions of isolation and cohorting until proven to be CRE-negative. These measures will reduce the hospitalization of CRE-positive patients among the general patient population, potentially preventing the spread of CRE.”

CRE are difficult-to-treat, multidrug-resistant organisms that are emerging in the U.S. A CRE strain of Klebsiella pneumoniae recently spread through the National Institutes of Health (NIH) hospital outside Washington, D.C., killing six people. Because of increased reports of these multidrug-resistant germs, the Centers for Disease Control and Prevention (CDC) recently alerted clinicians about the need for additional steps to prevent transmission.

Source: Elsevier; February 27, 2013.

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only